MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$6,012,458
EPS
-$0.07
Unit: Dollar
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue from collaborative arrangement
0
0
0
0
Research and development
10,826,549
14,070,107
10,261,236
13,333,329
General and administrative
7,797,973
7,879,886
7,215,365
7,877,126
Total operating expenses
18,624,522
21,949,993
17,476,601
21,210,455
Loss from operations
-18,624,522
-21,949,993
-17,476,601
-21,210,455
Interest income
363,847
439,593
449,337
552,108
Interest expense
-
-
0
0
Change in fair value of common stock warrant liabilities
-13,868,616
-4,137,703
-21,174,099
22,515,730
Loss (gain) on investment in affiliated entity
0
-2,103,688
-392,042
-589,618
Net unrealized gain on available-for-sale equity securities
94,221
79,077
9,999
205,259
Other expense, net
-1,714,620
-285,490
88
-1,938,236
Net gain
-6,012,458
-19,682,798
3,764,880
-45,496,672
Basic EPS
-0.07
-0.28
0.065
-0.87
Diluted EPS
-0.07
-0.28
0.065
-0.87
Basic Average Shares
81,619,113
69,101,910
57,933,252
52,168,694
Diluted Average Shares
81,619,113
69,101,910
57,933,252
52,168,694
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net gain
-$6,012,458
(74.44%↑ Y/Y)
Change in fair value of
common stock warrant...
-$13,868,616
(-838.47%↓ Y/Y)
Interest income
$363,847
(-40.42%↓ Y/Y)
Net unrealized gain
on...
$94,221
(-87.59%↓ Y/Y)
Loss from operations
-$18,624,522
(19.32%↑ Y/Y)
Other expense, net
-$1,714,620
(-143.84%↓ Y/Y)
Total operating
expenses
$18,624,522
(-19.32%↓ Y/Y)
Research and development
$10,826,549
(-25.44%↓ Y/Y)
General and
administrative
$7,797,973
(-8.94%↓ Y/Y)
Buy us a coffee
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)